Brought to you by 
CRISPR, Vertex partner in $3.6bn CRISPR-Cas9 gene editing collaboration; later expanded to other disease areas
27 Mar 2020
Executive Summary
CRISPR Therapeutics is lending its CRISPR-Cas9 gene editing technology to Vertex Pharmaceuticals Inc. as part of a four-year research collaboration aimed at discovering treatments to address the underlying genetic defects that cause or contribute to certain diseases, including cystic fibrosis and sickle cell disease.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com